T1	condition 139 176	Trastuzumab-Associated Cardiotoxicity
T2	eligibility 668 715	patients with HER2-positive early breast cancer
T5	control 793 800	placebo
T6	intervention-participants 1150 1162	Thirty-three
T7	intervention-participants 1194 1196	31
T8	control-participants 1222 1224	30
T9	outcome 1367 1392	no serious adverse events
T11	outcome 1648 1663	decline in LVEF
T10	outcome 1434 1471	left ventricular end diastolic volume
T12	iv-cont-mean 1520 1522	+7
T18	iv-cont-sd 1525 1533	14 mL/m2
T13	iv-cont-mean 1548 1553	+8 mL
T19	iv-cont-sd 1556 1563	9 mL/m2
T14	cv-cont-mean 1579 1581	+4
T20	cv-cont-sd 1584 1592	11 mL/m2
T15	iv-cont-mean 1711 1713	-1
T21	iv-cont-sd 1716 1718	5%
T16	iv-cont-mean 1749 1751	-3
T22	iv-cont-sd 1754 1756	4%
T17	cv-cont-mean 1771 1773	-5
T23	cv-cont-sd 1776 1778	5%
T3	intervention 765 788	perindopril, bisoprolol
T4	outcome-Measure 2132 2159	left ventricular remodeling
